Luma buy fleshes out SpectraScience's cancer detection portfolio:
This article was originally published in Clinica
Executive Summary
San Diego, California-based SpectraScience has expanded its reach in the cancer detection market with the acquisition of Luma Imaging, a developer of optical noninvasive cervical cancer diagnostic technology. Luma's FDA-approved cervical imaging system is designed as an easy-to-use adjunctive device to conventional colposcopy to improve the detection of cervical cancer. Clinical trials have shown that the product can detect over 25% more precancerous cells in the cervix than colposcopy alone. Luma's technology complements SpectraScience's WavSTAT system, which is also optics-based and noninvasive. The WavSTAT is approved for use in detecting precancer and cancer in the colon. SpectraScience is currently evaluating its technology for detecting precancers in the throat.